Phase 1 Trial: GDC-2992, A Novel Dual-Action AR Degrader Aiming to Overcome Resistance in Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxNewsletter 17/2025
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! This is AACR 2025 week, and there’s a lot to talk about regarding new treatments for solid tumors that could potentially include prostate cancer. Studies directly focused on prostate cancer have not yet been fully revealed, but I’ve already […]
Phase 1 Recruiting: IMP1734 (EIK1003), A New PARP1 Inhibitor for mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Recruiting: GSK5764227 Targets B7-H3 in mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxGrape Seed Extract Shows Potential to Slow Prostate Cancer Progression
/0 Comments/in Clinical Trial, Non-Metastatic, Phase 2/by MaxOvercoming Resistance in Metastatic Prostate Cancer: Repurposing Pimitespib
/0 Comments/in Drug repurposing, Preclinical Research/by MaxBA1106 Antibody Shows Promise in Early Trials In Solid Tumors
/0 Comments/in Clinical Trial, Not PCa related/by MaxQ702 Drug Shows Promise in Early Trials: Could Be Useful Against Prostate Cancer
/0 Comments/in Clinical Trial, Not PCa related/by MaxNezastomig (REGN5678): New Drug Combo Shows Promise In mCRPC, But Safety Is A Concern
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA MYC NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- OMNIRAY: a Phase 1 Clinical Trial for LY4257496 for mCRPC August 20, 2025
- Nutrition and Inflamation: New Research Unveils Five Universal Patient Clusters in Oncology August 19, 2025
- Nuanced Benefits of Fasting-Mimicking Diets: High Protein vs. Low Protein August 18, 2025
- Newsletter 33/2025 August 17, 2025